TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)

Starting soon · Phase 2/Phase 3

Conditions studied: Inflammatory Myopathy

In brief

The goal of this clinical trial is to evaluate the efficacy of Telitacicept in the treatment of inflammatory myopathy in patients with inflammatory diseases. The main question it aims to answer is: the safety and effectiveness of Telitacicept in treating inflammatory myopathy.

Key facts

Study ID

NCT07355257

Run by

Zhongming Qiu

People needed

30

Starts

2026-02-02

Expected to finish

2027-03-30

Last updated by the study team

2026-01-21

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years and ≤ 70 years.
• Patient has a confirmed diagnosis of inflammatory myopathy, meeting the 2017 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for idiopathic inflammatory myopathies.
• Inadequate response or intolerance to glucocorticoids and/or at least one immunosuppressant.
• The patient or their legal guardian provides written informed consent.

You may not qualify if…

• Female patients who are pregnant, breastfeeding, or planning a pregnancy during the trial period.
• Patients with active infections, such as herpes zoster, HIV, active tuberculosis, active hepatitis, HBsAg-positive patients, or HCV antibody-positive patients.
• Patients with positive test results indicating COVID-19 infection within 1 month prior to baseline.
• Patients with a history of or currently diagnosed malignancy.
• Patients with significant cardiovascular diseases (including severe arrhythmia), hepatic, renal, respiratory, endocrine, or hematological disorders, or any other medical condition that, in the investigator's judgment, would interfere with participation in the study or require hospitalization during the trial.
• Patients who have received intravenous immunoglobulin (IVIG) or plasmapheresis within 1 month prior to baseline.
• Patients who have received other targeted biologic therapies, such as rituximab, eculizumab, tocilizumab, etc., within 3 months prior to baseline.
• Patients who have received any live vaccine within 3 months prior to baseline or plan to receive any vaccine during the study period.
• Patients with a known allergy to human-derived biologics.
• Patients currently participating in another clinical trial.
• Patients deemed unsuitable for participation by the investigator for other reasons (e.g., severe psychiatric disorders).

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.